PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

University of Colorado Grants License to Cirena for RNA-Synthesis Technology

Foundational synthesis technology enables scalable modified 100-400nt RNA constructs, speeding design cycles and improving genome-editing precision

Cirena has secured a license to the University of Colorado Boulder’s patented RNA synthesis technology, giving researchers scalable access to high purity 100-400nt RNA constructs for next-generation therapeutics. The agreement brings to market an approach developed at CU Boulder enabling reliable synthesis of long RNA needed to support rapidly developing applications in CRISPR, functional genomics, and emerging RNA-therapeutic modalities.

This licensed thionocarbonate-based technology gives Cirena a significantly higher-yield route not achievable using previous phosphoramidite methods for RNA synthesis, enabling routine production of highly modified, long and ultra-long RNA constructs.

“The underlying patent estate represents years of excellent foundational work at CU Boulder. By commercializing through Cirena, researchers worldwide will finally have dependable access to long and ultra-long RNA constructs that have historically been difficult or impossible to obtain at scale,” said Bryn Rees (CU Boulder Senior Associate Vice Chancellor for Innovation and Partnerships).

“Demand for long and ultra-long RNA has grown rapidly as CRISPR, lncRNA and RNA-therapeutic programs advance, and this technology finally makes those constructs reliably accessible at scale,” said Doug Dellinger (Cirena CEO). “This agreement with the University of Colorado expands our ability to provide high‑purity long RNA to the global research community while maintaining rapid turnaround times.”

This licensing agreement represents a significant advance for researchers developing next generation RNA therapeutics, as it provides industry access to a scalable platform for producing long, high purity RNA that was previously unattainable with conventional synthesis technologies.

Researchers can learn about Cirena’s early customer program or request evaluation materials at www.cirena.com or by contacting RNAtechsupport@cirena.com. Cirena RNA products are intended for research use only.

About Cirena
Cirena provides long and ultra-long, high purity RNA for researchers in therapeutics, gene editing, and functional genomics. The company’s proprietary technology -developed at the University of Colorado Boulder by the teams of Prof. Marvin Caruthers (co-founder: Amgen, Applied Bioscience) and Dr. Douglas Dellinger (CU Boulder, Agilent) – enables rapid turnaround of 100+ nt RNA with exceptional purity. Cirena is headquartered at the BioFrontiers Institute at the University of Colorado Boulder. Cirena RNA products are intended for research use only.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026